Guro Løvik Goll

Senior researcher
https://orcid.org/0000-0002-8506-725X

View Google Scholar profile

See publications in PubMed

Education

Can.med, Faculty of Medicine, University of Oslo (1995)
Doctorate from the Faculty of Medicine, University of Oslo (2001)

Position

Senior Researcher, Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
Senior Consultant in Rheumatology, Clinic for Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital

Field of interest

Advanced drug treatment of inflammatory rheumatic disease
Biomarkers
Drug monitoring
Biosimilar medicines
Synovial biopsies
Autoimmunity
Vaccine response

Email

Telephone

+47 22451500

Visiting address

Diakonhjemmet Hospital
Diakonveien 12
0370 Oslo

Postal address

Diakohjemmet Hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

WP2 - PPhenotyping for personalized medicine

BioTest

Experimental precision medicine

WP2 - PPhenotyping for personalized medicine

MDR-RA

The Norwegian study for therapeutic pharmacovigilance

WP2 - PPhenotyping for personalized medicine

MoRA – monitoring aspects of rheumatoid arthritis

WP1 - Optimized medical interventions

NOR-SWITCH

Switching from originator to biosimilar in patients with inflammatory joint, intestinal or skin disease

WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive therapy

WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effectiveness of prescription drugs for rheumatoid arthritis

WP2 - PPhenotyping for personalized medicine

START

Early diagnosis of newly occurring arthritis

Publications

Publications retrieved from the National Science Archives (NVA):

Development of Machine Learning Models for Predicting Non-Remission in Early RA Highlights the Robust Predictive Importance of the RAID Score-Evidence from the ARCTIC Study

2025

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

2024

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumor necrosis factor inhibitors: a prospective cohort study

2024

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

2024

Efficacy of a Tumor Necrosis Factor inhibitor in chronic low back pain with Modic changes type 1: The BackToBasic study A randomized controlled trial

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

2023

Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway

2023

Hybrid and SARS-CoV-2 vaccine immunity in kidney transplant recipients

2023

Cytokine Patterns as Predictors of Antibiotic Treatment Effect in Chronic Low Back Pain with Modic Changes: Subgroup Analyzes of a Randomized Trial (AIM Study)

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

2023

Longitudinal changes of serum cytokines in patients with chronic low back pain and Modic changes

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

2023

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

2022

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

2022

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

2022

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

2022

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

2021

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia

2021

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

2021

Macrophage migration inhibitory factor: A potential biomarker for chronic low back pain in patients with Modic changes

2021

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

2020

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

2020

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

2020

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

2019

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial

2019

Biological drugs in rheumatology

2018

Confiance des rhumatologues quant au passage a un biosimilaire

2018

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

2017

Interleukin-15 Induces Interleukin-17 Production by Synovial T Cell Lines from Patients with Rheumatoid Arthritis

2011

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

2010

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

2010

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

2010

Guro Løvik Goll

Education

Position

Field of interest

Email

Telephone

Visiting address

Postal address

Projects

Publications

Publications retrieved from the National Science Archives (NVA):

Development of Machine Learning Models for Predicting Non-Remission in Early RA Highlights the Robust Predictive Importance of the RAID Score-Evidence from the ARCTIC Study

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumor necrosis factor inhibitors: a prospective cohort study

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Efficacy of a Tumor Necrosis Factor inhibitor in chronic low back pain with Modic changes type 1: The BackToBasic study A randomized controlled trial

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway

Hybrid and SARS-CoV-2 vaccine immunity in kidney transplant recipients

Cytokine Patterns as Predictors of Antibiotic Treatment Effect in Chronic Low Back Pain with Modic Changes: Subgroup Analyzes of a Randomized Trial (AIM Study)

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

Longitudinal changes of serum cytokines in patients with chronic low back pain and Modic changes

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

Macrophage migration inhibitory factor: A potential biomarker for chronic low back pain in patients with Modic changes

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial

Biological drugs in rheumatology

Confiance des rhumatologues quant au passage a un biosimilaire

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Interleukin-15 Induces Interleukin-17 Production by Synovial T Cell Lines from Patients with Rheumatoid Arthritis

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

Privacy Settings

Functional

Preferences